What’s JP Morgan’s price target on CSL shares?
Image source: Getty Images
CSL Ltd (ASX: CSL) shares have come under pressure over the past few years.
While the recent market rally has sent many ASX 200 stocks back toward their all-time highs, CSL remains materially behind.
The ASX 200 healthcare stock is often promoted as one of the highest quality companies on the ASX. In 2019, CSL rose around 50%.
However, shareholder returns have not reflected this profile in recent years.
Over the past 5 years, the share price has fallen 19%. For the year to date, it is down 15%, significantly underperforming the S&P/ASX 200 Index (ASX: XJO) which is up 4%.
Slower earnings per share (EPS) growth and rising debt as a result of the Vifor acquisition has driven underperformance.
Given…
